Antithrombin replacement 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Thrombate III (antithrombin III human) / Grifols
NCT00319228: Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate

Active, not recruiting
2/3
30
NA
Plasma-derived AT-III concentrate
Grifols Biologicals, LLC
Antithrombin III Deficiency
12/28
03/29
Atenativ (human antithrombin III) / Octapharma
ATN-106, NCT04918173 / 2021-004307-40: Efficacy of Atenativ in Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

Recruiting
3
38
Europe, US, RoW
Atenativ
Octapharma
Congenital Antithrombin Deficiency
12/25
12/25
NCT06096116: Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

Recruiting
3
120
Europe, US, RoW
Human plasma derived antithrombin, Placebo
Octapharma
Acquired Antithrombin Deficiency
12/26
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Thrombate III (antithrombin III human) / Grifols
NCT00319228: Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate

Active, not recruiting
2/3
30
NA
Plasma-derived AT-III concentrate
Grifols Biologicals, LLC
Antithrombin III Deficiency
12/28
03/29
Atenativ (human antithrombin III) / Octapharma
ATN-106, NCT04918173 / 2021-004307-40: Efficacy of Atenativ in Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

Recruiting
3
38
Europe, US, RoW
Atenativ
Octapharma
Congenital Antithrombin Deficiency
12/25
12/25
NCT06096116: Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

Recruiting
3
120
Europe, US, RoW
Human plasma derived antithrombin, Placebo
Octapharma
Acquired Antithrombin Deficiency
12/26
12/26

Download Options